Company news
Lantheus Holdings, Inc. news in 2021
Lantheus Holdings, Inc.'s news releases, calls and decks from 2021, newest first.
Lantheus Appoints Vivian Yao as Chief Human Resources Officer
November 30, 2021
Lantheus Announces PYLARIFY AI™ is Now Available
November 28, 2021
Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022
November 21, 2021
Lantheus Holdings Announces Presentations Featuring PYLARIFY® (Piflufolastat F 18), its PSMA-Targeted Prostate Cancer Imaging Agent, at Key Scientific Meetings
November 16, 2021
Lantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 15, 2021
Lantheus Holdings, Inc. Reports Third Quarter 2021 Financial Results
November 3, 2021
Lantheus Holdings to Present at Upcoming Investor Conferences
October 27, 2021
Lantheus Holdings to Host Third Quarter 2021 Earnings Conference Call and Webcast on November 4, 2021 at 8: 00 a.m. Eastern Time
October 20, 2021
Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network® (NCCN) Guidelines for Prostate Cancer
September 12, 2021
Lantheus and RefleXion Announce Development and Commercialization Collaboration with the Potential to Improve Future Prostate Cancer Treatment
September 12, 2021
Lantheus Announces Presentation at the 2021 American Urological Association (AUA) Annual Meeting
September 9, 2021
Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus’ Leadership in Prostate Cancer
July 28, 2021
Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results
July 27, 2021
Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8: 00 a.m. Eastern Time
July 13, 2021
Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting
June 13, 2021
Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer
May 26, 2021
Lantheus Holdings Announces Presentation Featuring ¹⁸F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting
May 20, 2021
Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference
May 19, 2021
Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results
May 3, 2021
EXINI Diagnostics AB, a Lantheus Company, Receives CE Mark Clearance for aPROMISE in Europe
May 2, 2021
Lantheus Grants Allegheny Health Network Exclusive Rights for the Use of its Microbubbles in Combination with Ultrasound Assisted Gene Therapy for the Development of a Proposed Treatment for Xerostomia
April 29, 2021
Lantheus Holdings to Host First Quarter 2021 Earnings Conference Call and Webcast on May 4, 2021 at 8: 00 a.m. Eastern Time
April 19, 2021
Lantheus Expands R&D Leadership Team with Key New Hires
April 6, 2021
Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel
March 31, 2021
Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria
March 29, 2021
Lantheus Announces Presentation Featuring AZEDRA® (iobenguane I 131) at ENDO 2021
March 21, 2021
Lantheus Announces Publication of PyL™ (18F-DCFPyL) Results from Pivotal Studies
February 28, 2021
Lantheus Reports Fourth Quarter and Full Year 2020 Financial Results
February 24, 2021
Lantheus Holdings to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 11, 2021
Lantheus Holdings to Host Fourth Quarter and Full Year 2020 Earnings Conference Call and Webcast on February 25, 2020 at 4: 30 p.m. Eastern Time
February 10, 2021
Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting
February 3, 2021
Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.
January 11, 2021